The SHIELD Citizens Act aims to restrict access to federal welfare programs, such as food assistance, Medicaid, and housing aid, exclusively to United States citizens. By amending existing laws, the bill removes eligibility for noncitizens, including lawfully domiciled residents, while preserving access to emergency medical care, disaster relief, and services like soup kitchens. The legislation includes a transition period allowing current recipients to keep their benefits for up to 180 days after the law takes effect, which is set to begin 180 days after enactment. This change directly impacts noncitizen families who currently rely on these safety net programs, narrowing the pool of eligible individuals to citizens only.
This bill, titled the Take Back Our Hospitals Act of 2026, would prohibit Medicare from paying hospitals or skilled nursing facilities owned or controlled by private equity funds, real estate investment trusts, or corporations owned by those funds. The law defines control as owning 10 percent or more of voting securities or having the power to direct management and policies through contracts or other means. Facilities currently owned by these firms would have a three-year transition period before the prohibition takes full effect. The bill also establishes joint and several liability, meaning the owning firm would be responsible for any penalties if the facility violates the rule, and provides for notice, hearings, and judicial review for affected facilities.
HR 7196 prohibits the District of Columbia Council from passing any law permitting euthanasia or assisted suicide. It directly affects DC residents and the Council by blocking the legalization of these practices within the District. The bill amends the Home Rule Act to add a new prohibition against enacting any law related to euthanasia or assisted suicide, and it repeals DC's existing 2016 Death With Dignity Act. These changes prevent the District from implementing such policies through legislation, regulations, or other legal mechanisms.
HR 3708, the "No Place for LGBTQ+ Hate Act," repeals five specific executive orders targeting LGBTQ+ rights and blocks federal funding for their implementation. It directly affects transgender, nonbinary, intersex, and gender-nonconforming individuals by reversing policies that: mandated discrimination in employment/healthcare (EO 14168), reinstated a military ban (EO 14183), restricted transgender youth healthcare (EO 14187), barred transgender female students from sports (EO 14201), and required schools to deny transgender existence (EO 14190). The bill’s key mechanism prohibits federal funds from being used to enforce these orders, effectively nullifying them. This is a procedural repeal bill focused on reversing specific executive actions, not creating new laws.
HR 54, the WHO Withdrawal Act, directs the U.S. President to withdraw the United States from the World Health Organization (WHO) Constitution upon enactment and prohibits all federal funding for U.S. participation in the WHO or any successor organization. The bill repeals the 1948 law that established U.S. membership and funding for WHO participation. This legislation directly affects all federal departments and agencies that handle international health funding and diplomatic engagement, ending U.S. financial and legal ties to the WHO.
HR 5075, the GRACE Act, requires schools receiving federal education funds to allow religious exemptions from vaccination requirements without requiring documentation. It directly affects K-12 public schools and school agencies that receive federal funding, as they must permit students (or their parents/guardians for minors under 18) to skip vaccinations based on religious belief. The key provision mandates that schools cannot demand proof of a religious belief to grant such exemptions. This changes how schools handle vaccination policies for enrollment, attendance, and school activities when receiving federal education dollars.
HR 401, the "No Taxpayer Funding for the World Health Organization Act," prohibits the U.S. government from providing any assessed or voluntary contributions to the World Health Organization (WHO) starting on the day the bill becomes law. This directly affects the WHO, which would lose U.S. funding through these specific channels, and the U.S. government, which would no longer allocate taxpayer money for this purpose. The key mechanism is a statutory ban that overrides existing law, requiring immediate cessation of such payments without needing additional authorization. The bill does not impact other U.S. international health programs or the WHO's broader operations.
This bill prohibits doctors from performing abortions based solely on a Down syndrome diagnosis. It requires providers to ask patients about such diagnoses before an abortion and inform them of the ban. Violations could result in criminal penalties (up to 5 years in prison) or civil lawsuits seeking damages for the patient or family. The law applies to all abortions performed in the U.S. or transported across state lines for this specific purpose. It does not restrict other abortion procedures or create a new right to abortion.
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
SJRES 103 is a congressional disapproval resolution targeting a Department of Veterans Affairs (VA) rule on reproductive health services for veterans. The resolution, if passed, would block the VA rule from taking effect by invoking the Congressional Review Act (Chapter 8 of Title 5, U.S. Code), meaning the rule published in the Federal Register (December 31, 2025) would have no legal force. This directly affects the VA’s ability to implement new guidelines for reproductive health services at its facilities, preserving existing policies instead. The resolution does not create new policy but halts a specific administrative rule.
